|
|
News Breaks | | | | December 11, 2012 | | 08:08 EDT |  | ARIA | ARIAD announces 12-month data from PACE trial of ponatinib
ARIAD Pharmaceuticals announced twelve-month follow-up data from the pivotal PACE trial of ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated patients with advanced forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The study now shows that 57 percent of accelerated-phase CML patients in the trial, including 50 percent of patients with the T315I mutation, achieved a major hematologic response, the primary end-point for patients with advanced disease in the trial. | |
|
News For ARIA From The Last 14 Days Check below for free stories on ARIA the last two weeks. |
|
|
| May 17, 2013 | | 08:22 EDT |  | ARIA | ARIAD shares should be bought on weakness, says BMO Capital
 Subscribe for More Information | | | May 16, 2013 | | 07:29 EDT |  | ARIA | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | | | May 7, 2013 | | 12:02 EDT | | ARIA | ARIAD management to meet with JMP Securities
Subscribe for More Information | | | 07:39 EDT |  | ARIA | ARIAD reports Q1 EPS (36c), consensus (38c)
Subscribe for More Information | |
|
|
|
|
|
|
